HOME >> MEDICINE >> NEWS
Passing stop sign cures gene disease

awbacks. The body absorbs it poorly, so it must be injected or inhaled. And inhaling is fine for cystic fibrosis, but of little use for conditions such as muscular dystrophy. The antibiotic can also cause rare but serious side effects such as hearing loss and kidney damage.

That's where PTC124 comes in: it was designed from the start to have similar properties to gentamicin but to be safer and more easily absorbed. "We are really in a different situation now, where we are trying to identify drugs based on how they should act," says Langdon Miller, chief medical officer of PTC Therapeutics in New Jersey.

The drug was screened out of a pool of 175,000 synthetic molecules. Pre-clinical tests so far indicate that it is more potent than gentamicin and seems to have very low toxicity. "This could have very far-reaching effects," claims David Bedwell, a microbiologist at the University of Alabama in Birmingham, who has tested the compound in his lab and is collaborating with the company.

In mice with muscular dystrophy the drug restores expression of the dystrophin protein found on the surface of muscle cells. Tests suggest the muscles regain some of their normal characteristics. Tests on mice with cystic fibrosis also suggest PTC124 restores production of functional CFTR.

All the results remain unpublished, though researchers working with the company say they hope to publish as soon as intellectual property issues are resolved. Miller says the company hopes to start clinical trials with healthy volunteers as early as next year.

But a premature stop mutation will not always be the cause of a particular genetic disease. So even if PTC124 or gentamicin make it to the market for treating genetic diseases, they will not be a magical cure for everyone.


'"/>

Contact: Claire Bowles
claire.bowles@rbi.co.uk
44-207-331-2751
New Scientist
15-Oct-2003


Page: 1 2

Related medicine news :

1. Procedure cures atrial fibrillation
2. First UK cases of previously rare disease reported in gay men
3. Uric acid and heart disease
4. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
5. Risky surgery not always necessary to treat cervical disease
6. Stanford patient is first to test new treatment for peripheral arterial disease
7. Community care tops medical care at preventing heart disease in black Americans
8. Neuronal death and processing of Tau protein in Alzheimers disease
9. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
10. Reducing hostility in young coronary artery disease patients is important piece of rehabilitation
11. Study finds direct association between cardiovascular disease and periodontal bacteria

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Passing stop sign cures gene disease

(Date:7/28/2014)... Cape Regional Medical Center, is ... technology solution in an effort to streamline its ... with their New Jersey health information exchange (NJSHINE). ... in New Jersey, serves the local population and ... of inpatient and outpatient services. With a strong ...
(Date:7/28/2014)... News) -- Endurance runners are far more likely to ... according to a new study. The researchers ... warm climates are actually 10 times more likely to ... common sudden death of a young and apparently healthy ... irregular heartbeat, often gets a lot more media attention. ...
(Date:7/28/2014)... The Oakwood Foundation celebrated a major gift this ... PC that will benefit each community we serve for ... The HBWS group is among the Foundation’s largest physician ... donations. Through their latest gift, they will be one ... Classic for the next 6 years; provide state-of-the-art technology ...
(Date:7/28/2014)... one of two dopamine-producing regions in the brain was ... isoflurane or propofol. In the August issue of ... report that rats anesthetized with continuous doses of either ... up in response to electrical stimulation delivered to the ... major dopamine-releasing area, the substantia nigra, did not induce ...
(Date:7/28/2014)... 2014 The report, “Blowing Agents ... - Trends and Forecasts to 2019” defines and ... and forecasting of the global consumption volume and ... tables with 39 figures spread through 226 Pages ... http://www.marketsandmarkets.com/Market-Reports/blowing-agents-market-71329121.html , Blowing agents are highly utilized ...
Breaking Medicine News(10 mins):Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Heat Stroke a Greater Threat to Endurance Runners Than Heart Problems: Study 2Health News:Stimulation of brain region restores consciousness to animals under general anesthesia 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 3Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 4
(Date:7/28/2014)... Research and Markets  has announced the addition of the ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... pain in the human body,s joints such as wrists, fingers, ... the tissues that surround the joints and in other organs. ... usually just mild pain around the joints coupled with stiffness ...
(Date:7/28/2014)... July 28, 2014  Syneron Medical Ltd. (NASDAQ: ... announced today that its new PicoWay® device has received ... and colors and pigmented lesions on any skin type. ... with 532nm and 1064nm wavelengths, which utilizes Syneron,s proprietary ... pulses which are trillionths of a second, known as ...
(Date:7/28/2014)... Concord Medical Services Holdings Limited ("Concord Medical" ... leading specialty hospital management solution provider and operator of ... in China , today announced that ... a special cash dividend of US$0.30 per ordinary share ... Company,s outstanding ordinary shares. The total expense for the ...
Breaking Medicine Technology:Global Rheumatoid Arthritis Drugs Market 2014-2018 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4Concord Medical Declares Special Dividend 2
Cached News: